rhodanine has been researched along with Breast-Neoplasms* in 4 studies
1 review(s) available for rhodanine and Breast-Neoplasms
Article | Year |
---|---|
Moving toward a new horizon for the aldose reductase inhibitor epalrestat to treat drug-resistant cancer.
Epalrestat (EPA) is a potent inhibitor of aldose reductases AKR1B1 and AKR1B10, used for decades in Japan for the treatment of diabetic peripheral neuropathy. This orally-active, brain-permeable small molecule, with a relatively rare and essential 2-thioxo-4-thiazolidinone motif, functions as a regulator intracellular carbonyl species. The repurposing of EPA for the treatment of pediatric rare diseases, brain disorders and cancer has been proposed. A detailed analysis of the mechanism of action, and the benefit of EPA to combat advanced malignancies is offered here. EPA has revealed marked anticancer activities, alone and in combination with cytotoxic chemotherapy and targeted therapeutics, in experimental models of liver, colon, and breast cancers. Through inhibition of AKR1B1 and/or AKR1B10 and blockade of the epithelial-mesenchymal transition, EPA largely enhances the sensitivity of cancer cells to drugs like doxorubicin and sorafenib. EPA has revealed a major anticancer effect in an experimental model of basal-like breast cancer and clinical trials have been developed in patients with triple-negative breast cancer. The repurposing of the drug to treat chemo-resistant solid tumors seems promising, but more studies are needed to define the best trajectory for the positioning of EPA in oncology. Topics: Aldehyde Reductase; Breast Neoplasms; Child; Enzyme Inhibitors; Female; Humans; Rhodanine; Thiazolidines | 2022 |
3 other study(ies) available for rhodanine and Breast-Neoplasms
Article | Year |
---|---|
A two-pronged photodynamic nanodrug to prevent metastasis of basal-like breast cancer.
A two-pronged concept combining photodynamic therapy (PDT) and epithelial-mesenchymal transition (EMT) blockade in a minimalist nanoplatform was proposed to combat basal-like breast cancer (BLBC) metastasis. Based on PDT-mediated tumor killing and epalrestat (Epa)-mediated EMT blockade, as-prepared Ce6/Epa nanoparticles prevented BLBC metastasis effectively in vivo, providing a very promising two-pronged strategy against BLBC metastasis. Topics: Animals; Apoptosis; Breast Neoplasms; Cell Proliferation; Chlorophyllides; Enzyme Inhibitors; Epithelial-Mesenchymal Transition; Female; Humans; Lung Neoplasms; Mice; Mice, SCID; Nanoparticles; Photochemotherapy; Porphyrins; Radiation-Sensitizing Agents; Rhodanine; Thiazolidines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Small molecule inhibition of arylamine N-acetyltransferase Type I inhibits proliferation and invasiveness of MDA-MB-231 breast cancer cells.
Arylamine N-acetyltransferase 1 is a phase II metabolizing enzyme that has been associated with certain breast cancer subtypes. While it has been linked to breast cancer risk because of its role in the metabolic activation and detoxification of carcinogens, recent studies have suggested it may be important in cell growth and survival. To address the possible importance of NAT1 in breast cancer, we have used a novel small molecule inhibitor (Rhod-o-hp) of the enzyme to examine growth and invasion of the breast adenocarcinoma line MDA-MB-231. The inhibitor significantly reduced cell growth by increasing the percent of cells in G2/M phase of the cell cycle. Rhod-o-hp also reduced the ability of the MDA-MB-231 cells to grow in soft agar. Using an in vitro invasion assay, the inhibitor significantly reduced the invasiveness of the cells. To test whether this effect was due to inhibition of NAT1, the enzyme was knocked down using a lentivirus-based shRNA approach and invasion potential was significantly reduced. Taken together, the results of this study demonstrate that NAT1 activity may be important in breast cancer growth and metastasis. The study suggests that NAT1 is a novel target for breast cancer treatment. Topics: Adenocarcinoma; Arylamine N-Acetyltransferase; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; Female; Humans; Isoenzymes; Neoplasm Invasiveness; Neoplasm Metastasis; Rhodanine | 2010 |
Selective small molecule inhibitors of the potential breast cancer marker, human arylamine N-acetyltransferase 1, and its murine homologue, mouse arylamine N-acetyltransferase 2.
The identification, synthesis and evaluation of a series of rhodanine and thiazolidin-2,4-dione derivatives as selective inhibitors of human arylamine N-acetyltransferase 1 and mouse arylamine N-acetyltransferase 2 is described. The most potent inhibitors identified have submicromolar activity and inhibit both the recombinant proteins and human NAT1 in ZR-75 cell lysates in a competitive manner. (1)H NMR studies on purified mouse Nat2 demonstrate that the inhibitors bind within the putative active site of the enzyme. Topics: Animals; Arylamine N-Acetyltransferase; Binding Sites; Biomarkers, Tumor; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Isoenzymes; Mice; Rhodanine; Thiazolidinediones | 2009 |